TSTickerStarGet alerts

Jaguar Health Reports Q3 2026 Results; Revenue Down 24% YoY as Company Transitions to Licensing Model

Jaguar Health reported Q3 2026 total revenue of $2.34 million, down 24% year-over-year from $3.08 million, as the company transitioned to a licensing model following its January 2026 agreement with Future Pak for Mytesi and Canalevia-CA1 U.S. commercialization. Net loss improved to $5.83 million from $9.65 million in Q3 2025, while the company significantly reduced outstanding debt by $10.1 million during the quarter. The company expects to file an NDA for crofelemer powder for oral solution for microvillus incl...

Share this story

Key takeaways

  • Revenue mix shifted to licensing: product revenue fell to $551,000 from $3.04 million in Q3 2025 while license and grant revenue rose to $1.79 million from $42,000, reflecting recognition of upfront payments under the January 2026 Future Pak agreement for Mytesi and Canalevia-CA1 U.S. commercialization.

  • The company dissolved its salesforce and moved to a licensing model in which product revenues now flow to Future Pak, with strategic focus shifting from commercial sales to research and development.

  • Operating expenses were reduced by $2.0 million in the quarter, partially offsetting lower revenues and narrowing the operating loss to $6.02 million from $7.24 million.

  • Outstanding debt was reduced by $10.1 million during Q3 2026, including full repayment of the Streeterville New Note through a stock exchange transaction.

  • Non-GAAP Recurring EBITDA loss improved to $5.03 million from $9.03 million in the prior-year quarter.

  • The company issued no full-year revenue or earnings guidance; the only forward-looking item disclosed is the planned mid-2027 NDA filing for crofelemer powder for oral solution for microvillus inclusion disease.

  • An investor webcast to discuss Q3 2026 financials and company updates is scheduled for November 17, 2026 at 8:30 a.m. Eastern.

Key metrics

Total RevenueQ3 2026
$2.34M-24.0%
License and Grant RevenueQ3 2026
$1.79M4166.7%
Product Revenue, NetQ3 2026
$551K-81.9%
Loss from OperationsQ3 2026
$6.02M16.8% improvement
Net LossQ3 2026
$5.83M39.6% improvement
Net Loss Per Share (Basic and Diluted)Q3 2026
$9.2399.5% improvement
Non-GAAP Recurring EBITDAQ3 2026
$5.03M44.2% improvement
Non-GAAP EBITDAQ3 2026
$5.59M38.1% improvement

Disclosure changes

  • Business model transition

    Effective January 12, 2026, Jaguar entered a U.S. commercial licensing agreement with Future Pak, making Future Pak the exclusive U.S. marketer for Mytesi and Canalevia-CA1. Jaguar now operates as a distribution entity focused on R&D for its crofelemer powder-for-oral-solution formulation for rare-disease indications.

    Fundamental shift in business model affecting revenue recognition, operating expenses, and strategic focus
  • Debt reduction

    Company significantly reduced outstanding debt balance by $10.1 million in Q3 2026, including full repayment and cancellation of the Streeterville New Note through a stock exchange transaction.

    Material improvement in balance sheet and reduction in financial obligations
  • Revenue concentration

    License revenues from the $16 million upfront payment and $3 million early termination payment under the Future Pak agreement were recognized in Q1 2026. Total deferred revenue as of September 30, 2026 was $425,000.

    Change in revenue recognition timing and composition

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow JAGX in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert